IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published May 13, 2026
Medical Professional
Curative Potential of 2L CAR-T/liso-cel
Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)
Laura van 't Veer, PhD
Dr. Arnab Basu reviews ctDNA risk status as a predictor of recurrence in bladder cancer (Video 2/3)
Arnab Basu, MD
Dr. Arnab Basu discusses ctDNA as a predictive marker in bladder cancer (Video 1/3)
Arnab Basu, MD
Dr. Manali Kamdar describes best practices and impact of timing for CAR-T utilization in patients with LBCL (Video 3/3)
Manali Kamdar, MD
Dr. Edgardo Santos describes the management of patients receiving SQ amivantamab-based regimens (Video 3/3)
Edgardo Santos, MD
Dr. Amer Zeidan describes the patient management with luspatercept including RS negative and EPO <200 (Video 3/3)
Amer Zeidan, MD